Background
MGC030 is a preclinical ADC that targets an undisclosed antigen expressed across several solid tumors. There are currently no approved therapeutics for this target.
MGC030 has demonstrated potent anti-tumor activity in multiple in vivo models and an encouraging preliminary safety and tolerability profile in exploratory cyno tox studies.
An IND application to the U.S. Food and Drug Administration (FDA) for MGC030 is planned for 2026.
Pre-Clinical Development
Please refer to our most recent corporate deck on our Events & Presentations page for the latest clinical information available on MGC030.
Our Rights
MacroGenics retains global rights to MGC030.
Presentations & Publications
Relevant Publications and Presentations can be found at https://macrogenics.com/publications/.
The safety and efficacy of investigational agents and/or investigational uses of approved products have not been established.